Kindstar Globalgene Technology (HKSE:09960) ROCE % : 1.32% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Kindstar Globalgene Technology ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kindstar Globalgene Technology's annualized ROCE % for the quarter that ended in Jun. 2024 was 1.32%.

Kindstar Globalgene Technology ROCE % Historical Data

The historical data trend for Kindstar Globalgene Technology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kindstar Globalgene Technology ROCE % Chart

Kindstar Globalgene Technology Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-594.33

-77.46

2.93

1.76

Kindstar Globalgene Technology Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial						5.11	0.86	3.39	0.10	1.32

Kindstar Globalgene Technology ROCE % Calculation

Kindstar Globalgene Technology's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	56.172	/	( ( (4160.146 - 962.109)	+	(4013.303 - 813.521) )	/ 2 )
	=	56.172	/	( (3198.037	+	3199.782)	/ 2 )
	=	56.172	/	3198.9095
	=	1.76 %

Kindstar Globalgene Technology's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	42.52	/	( ( (4013.303 - 813.521)	+	(4122.384 - 875.586) )	/ 2 )
	=	42.52	/	( ( 3199.782	+	3246.798 )	/ 2 )
	=	42.52	/	3223.29
	=	1.32 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Kindstar Globalgene Technology (HKSE:09960) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kindstar Globalgene Technology ROCE % Related Terms

Thank you for viewing the detailed overview of Kindstar Globalgene Technology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kindstar Globalgene Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Kindstar Globalgene Technology Inc (HKSE:09960) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Biolake D2-1, 666 Gaoxin Road, East Lake High Tech Zone, Hubei Province, Wuhan, CHN

Website

https://www.kindstar.com.cn

Kindstar Globalgene Technology Inc is principally engaged in the provision of clinical testing services in China. It organizes the business into the following segments; hematology testing, genetic disease and rare disease testing, infectious disease testing, oncology testing, neurology testing, maternity-related testing, COVID-19-related testing, routine testing, scientific research services and CRO, and other segments provide testing services for R&D projects and others and miscellaneous services.

Executives

Cpechina Fund Iii, L.p.	2201 Interest of corporation controlled by you
Ck Lab Tech Investment Limited	2101 Beneficial owner
Cpe Funds Iii Limited	2201 Interest of corporation controlled by you
Cpe Holdings International Limited	2201 Interest of corporation controlled by you
Cpe Holdings Limited	2201 Interest of corporation controlled by you
Huang Shiang	2101 Beneficial owner
Tu Zanbing
Huang Zuie-chin	2101 Beneficial owner
Ningbo Meishan Bonded Port Zone Ruifu Bojian Investment Management Co., Ltd.
Jackson Hole Trust Company
Huang Bo
Kernelstar Limited	2301 Trustee
Kastle Limited	2301 Trustee
Guo Gui-rong	2202 Interest of your spouse
Morningside Holdings (asia) Limited	2201 Interest of corporation controlled by you

Kindstar Globalgene Technology Headlines

No Headlines